{ "nodes": [ [ "4URU The crystal structure of H-Ras and SOS in complex with ligands", "PDB_STRUCTURE" ], [ "trametinib", "DRUG" ], [ "Panitumumab", "DRUG" ], [ "adagrasib", "DRUG" ], [ "PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER", "COMPOUND" ], [ "PIK3CA", "GENE" ], [ "Fluorouracil", "DRUG" ], [ "capivasertib", "COMPOUND" ], [ "S-Adenosylmethionine", "COMPOUND" ], [ "NVP-BKM120", "COMPOUND" ], [ "GUANOSINE-5'-DIPHOSPHATE", "COMPOUND" ], [ "Paclitaxel", "DRUG" ], [ "Fulvestrant", "DRUG" ], [ "DOT1L", "GENE" ], [ "5XGI Crystal structure of PI3K complex with an inhibitor", "PDB_STRUCTURE" ], [ "Alpelisib", "DRUG" ], [ "sotorasib", "DRUG" ], [ "KRAS", "GENE" ], [ "5DTM Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]", "PDB_STRUCTURE" ], [ "Oxaliplatin", "DRUG" ], [ "SOS1", "GENE" ], [ "Osteocalcin", "COMPOUND" ], [ "Permethrin", "DRUG" ], [ "Irinotecan", "DRUG" ], [ "Cetuximab", "DRUG" ], [ "Trastuzumab", "DRUG" ], [ "EPZ-5676", "COMPOUND" ], [ "MK 2206", "COMPOUND" ], [ "4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide", "COMPOUND" ], [ "Histone-Lysine N-Methyltransferase", "COMPOUND" ], [ "Etoposide", "DRUG" ], [ "AZD 6244", "COMPOUND" ], [ "venetoclax", "DRUG" ] ], "edges": [ [ [ "PIK3CA", "Paclitaxel" ], 7.382791500000001, [ [ "Rong Qin, Xiangyang Wang, Tingting Fan, Ting Wu, Chao Lu, Xun Shao, Liang Yin (2024). Bilateral inflammatory recurrence of HER-2 positive breast cancer: a unique case report and literature review. Frontiers in oncology, 1276637. https://doi.org/10.3389/fonc.2024.1276637 PMID: 38283858", "38283858" ], [ "Tomomi Nishimura, Ravi Velaga, Norikazu Masuda, Kosuke Kawaguchi, Shuji Kawaguchi, Masahiro Takada, Yurina Maeshima, Sunao Tanaka, Yuichiro Kikawa, Takayuki Kadoya, Hiroko Bando, Rikiya Nakamura, Yutaka Yamamoto, Takayuki Ueno, Hiroyuki Yasojima, Hiroshi Ishiguro, Satoshi Morita, Shinji Ohno, Hironori Haga, Fumihiko Matsuda, Seishi Ogawa, Masakazu Toi (2024). Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors. Cancer science, 3928-3942. https://doi.org/10.1111/cas.16339 PMID: 39375938", "39375938" ], [ "Hang Lu, Xin Yu, Zhiliang Xu, Jingwen Deng, Master Jingwen Zhang, Yimin Zhang, Shengrong Sun (2024). Prognostic Value of IGFBP6 in Breast Cancer: Focus on Glucometabolism. Technology in cancer research & treatment, 15330338241271998. https://doi.org/10.1177/15330338241271998 PMID: 39275851", "39275851" ], [ "Isis de Araújo Ferreira Muniz, Megan Araujo, Jenna Bouassaly, Fatemeh Farshadi, Mai Atique, Khashayar Esfahani, Paulo Rogerio Ferreti Bonan, Michael Hier, Marco Mascarella, Alex Mlynarek, Moulay Alaoui-Jamali, Sabrina Daniela da Silva (2024). Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer. International journal of molecular sciences. https://doi.org/10.3390/ijms25074009 PMID: 38612819", "38612819" ], [ "Robert Roskoski (2024). Targeted and cytotoxic inhibitors used in the treatment of breast cancer. Pharmacological research, 107534. https://doi.org/10.1016/j.phrs.2024.107534 PMID: 39631485", "39631485" ], [ "A Grinshpun, S Ren, N Graham, M K DeMeo, E Wrabel, J Carter, N Tayob, A Pereslete, E Hamilton, D Juric, E L Mayer, S M Tolaney, I E Krop, O Metzger (2024). Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer. ESMO open, 103465. https://doi.org/10.1016/j.esmoop.2024.103465 PMID: 38833970", "38833970" ], [ "Aihua Guo, Peilin Zhong, Linghua Wang, Xiurong Lin, Mei Feng (2024). Prognosis and immunotherapeutic implications of molecular classification of cervical cancer based on immunophenoscore-related genes. Journal of biomolecular structure & dynamics, 1-16. https://doi.org/10.1080/07391102.2024.2404545 PMID: 39308337", "39308337" ], [ "S Pignata, D Califano, D Lorusso, L Arenare, M Bartoletti, U De Giorgi, C Andreetta, C Pisano, G Scambia, D Lombardi, A Farolfi, S Cinieri, A Passarelli, V Salutari, C De Angelis, C Mignogna, D Priolo, E D Capoluongo, S Tamberi, G L Scaglione, V Arcangeli, R De Cecio, G Scognamiglio, F Greco, A Spina, M Turinetto, D Russo, V Carbone, C Casartelli, C Schettino, F Perrone (2024). MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 667-676. https://doi.org/10.1016/j.annonc.2024.04.007 PMID: 38704093", "38704093" ], [ "Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, Carlos Barrios, Joyce O'Shaughnessy, Steven J Isakoff, Shigehira Saji, Ruffo Freitas-Junior, Manuel Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew J Wongchenko, Sarah-Jayne Reilly, Nicholas Turner (2024). Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 4329-4338. https://doi.org/10.1158/1078-0432.CCR-24-0465 PMID: 39058425", "39058425" ], [ "Mohammad Alwahsh, Amani Al-Doridee, Suhair Jasim, Oriana Awwad, Roland Hergenröder, Lama Hamadneh (2024). Cytotoxic and molecular differences of anticancer agents on 2D and 3D cell culture. Molecular biology reports, 721. https://doi.org/10.1007/s11033-024-09669-1 PMID: 38829450", "38829450" ] ] ], [ [ "PIK3CA", "capivasertib" ], 4.021084, [ [ "Adrish Sen, Salmaan Khan, Stefano Rossetti, Aaron Broege, Ian MacNeil, Ann DeLaForest, Jhomary Molden, Laura Davis, Charles Iversrud, Megan Seibel, Ross Kopher, Stephen Schulz, Lance Laing (2025). Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. Molecular oncology, 225-247. https://doi.org/10.1002/1878-0261.13703 PMID: 39092562", "39092562" ], [ "Matt Shirley (2024). Capivasertib: First Approval. Drugs, 337-346. https://doi.org/10.1007/s40265-024-01998-6 PMID: 38388873", "38388873" ], [ "Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, Rene P Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist (2024). mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors. Cancer research communications, 2058-2074. https://doi.org/10.1158/2767-9764.CRC-24-0113 PMID: 38954770", "38954770" ], [ "Mafalda Oliveira, Hope S Rugo, Sacha J Howell, Florence Dalenc, Javier Cortes, Henry L Gomez, Xichun Hu, Masakazu Toi, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Zbigniew Nowecki, Yeon Hee Park, Joo Hyuk Sohn, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Marta Fulford, Haylee Andrews, Ian Wadsworth, Celina D'Cruz, Nicholas C Turner, (2024). Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 1231-1244. https://doi.org/10.1016/S1470-2045(24)00373-5 PMID: 39214106", "39214106" ], [ "Iseult M Browne, Alicia F C Okines (2024). Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer. Cancers. https://doi.org/10.3390/cancers16122259 PMID: 38927964", "38927964" ], [ "K Fanucci, A Giordano, T Erick, S M Tolaney, S Sammons (2024). Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer. ESMO open, 103997. https://doi.org/10.1016/j.esmoop.2024.103997 PMID: 39674130", "39674130" ], [ "Victor Heurtier, Alexandre de Nonneville (2024). [Capivasertib in combination with fulvestrant in locally advanced or metastatic RH+ HER2- breast cancer with PIK3CA, AKT1 or PTEN alteration, after first-line hormonal therapy]. Bulletin du cancer, 997-998. https://doi.org/10.1016/j.bulcan.2024.08.010 PMID: 39317592", "39317592" ], [ "M Sirico, F Jacobs, C Molinelli, Guilherme Nader-Marta, V Debien, H Faith Dewhurst, M Palleschi, F Merloni, C Gianni, U De Giorgi, Evandro de Azambuja (2024). Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond. Critical reviews in oncology/hematology, 104404. https://doi.org/10.1016/j.critrevonc.2024.104404 PMID: 38815877", "38815877" ], [ "Ursula Grazini, Aleksandra Markovets, Lucy Ireland, Daniel O'Neill, Benjamin Phillips, Man Xu, Matthias Pfeifer, Tereza Vaclova, Matthew J Martin, Ludovic Bigot, Luc Friboulet, Ryan Hartmaier, Maria E Cuomo, Simon T Barry, Paul D Smith, Nicolas Floc'h (2024). Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations. Clinical cancer research : an official journal of the American Association for Cancer Research, 4143-4154. https://doi.org/10.1158/1078-0432.CCR-23-2540 PMID: 38630555", "38630555" ], [ "Midori Morita, Ryo Tsunashima, Tetsuhiro Yoshinami, Masaki Ishida, Masahiro Iwasaku, Sae Kitano, Chikage Kato, Koichi Sakaguchi, Koichi Takayama, Yasuto Naoi (2024). A 5-year review of genomic medicine in breast cancer: insights from C-CAT data on 3776 Japanese patients. Breast cancer (Tokyo, Japan). https://doi.org/10.1007/s12282-024-01656-5 PMID: 39630210", "39630210" ] ] ], [ [ "DOT1L", "EPZ-5676" ], 70.7363, [ [ "Yaqi Zhang, Yinu Wang, Andres Valdivia, Hao Huang, Daniela Matei (2023). DOT1 L Regulates Ovarian Cancer Stem Cells by Activating β-catenin Signaling. Molecular cancer research : MCR, 140-154. https://doi.org/10.1158/1541-7786.MCR-22-0418 PMID: 36318113", "36318113" ], [ "Yang Si, Corentin Bon, Magdalena Barbachowska, Veronique Cadet-Daniel, Corinne Jallet, Laura Soresinetti, Mikaël Boullé, Magalie Duchateau, Mariette Matondo, Fabrice Agou, Ludovic Halby, Paola B Arimondo (2022). A novel screening strategy to identify histone methyltransferase inhibitors reveals a crosstalk between DOT1L and CARM1. RSC chemical biology, 456-467. https://doi.org/10.1039/d1cb00095k PMID: 35441144", "35441144" ], [ "Yan Yi, Shenglei Ge (2022). Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. Journal of hematology & oncology, 35. https://doi.org/10.1186/s13045-022-01251-1 PMID: 35331314", "35331314" ], [ "Hetakshi Kurani, Seyedeh Fatemeh Razavipour, Kuzhuvelil B Harikumar, Matthew Dunworth, Andrew J Ewald, Apsra Nasir, Gray Pearson, Derek Van Booven, Zhiqun Zhou, Diana Azzam, Claes Wahlestedt, Joyce Slingerland (2022). DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1948-1965. https://doi.org/10.1158/1078-0432.CCR-21-1299 PMID: 35135840", "35135840" ], [ "Carrie A Malcom, Anamika Ratri, Joanna Piasecka-Srader, Shaon Borosha, V Praveen Chakravarthi, Nehemiah S Alvarez, Jay L Vivian, Timothy A Fields, M A Karim Rumi, Patrick E Fields (2021). Primitive Erythropoiesis in the Mouse is Independent of DOT1L Methyltransferase Activity. Frontiers in cell and developmental biology, 813503. https://doi.org/10.3389/fcell.2021.813503 PMID: 35111761", "35111761" ], [ "Suresh Chava, Suresh Bugide, Yvonne J K Edwards, Romi Gupta (2021). Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis. Oncogenesis, 48. https://doi.org/10.1038/s41389-021-00339-6 PMID: 34253709", "34253709" ], [ "Katelyn E Heimbruch, Joseph B Fisher, Cary T Stelloh, Emily Phillips, Michael H Reimer, Adam J Wargolet, Alison E Meyer, Kirthi Pulakanti, Aaron D Viny, Jessica J Loppnow, Ross L Levine, John Anto Pulikkan, Nan Zhu, Sridhar Rao (2021). DOT1L inhibitors block abnormal self-renewal induced by cohesin loss. Scientific reports, 7288. https://doi.org/10.1038/s41598-021-86646-9 PMID: 33790356", "33790356" ], [ "Derek H Janssens, Michael P Meers, Steven J Wu, Ekaterina Babaeva, Soheil Meshinchi, Jay F Sarthy, Kami Ahmad, Steven Henikoff (2021). Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia. Nature genetics, 1586-1596. https://doi.org/10.1038/s41588-021-00941-9 PMID: 34663924", "34663924" ], [ "Wanlin Yang, Hongshuang Yu, Jiefang Huang, Xiang Miao, Qiwei Wang, Yanan Wang, Yiji Cheng, Shan He, Fang Zhao, Lijun Meng, Bei Wang, Fengtao Qian, Xiaohui Ren, Min Jin, Yuting Gu, Yanyun Zhang, Wei Cai (2021). Inhibition of Dot1L Alleviates Fulminant Hepatitis Through Myeloid-Derived Suppressor Cells. Cellular and molecular gastroenterology and hepatology, 81-98. https://doi.org/10.1016/j.jcmgh.2021.01.013 PMID: 33497867", "33497867" ], [ "Florian Perner, Jayant Y Gadrey, Yijun Xiong, Charles Hatton, Benjamin K Eschle, Andreas Weiss, Frédéric Stauffer, Christoph Gaul, Ralph Tiedt, Jennifer A Perry, Scott A Armstrong, Andrei V Krivtsov (2020). Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood, 1983-1988. https://doi.org/10.1182/blood.2020006113 PMID: 32575123", "32575123" ] ] ], [ [ "KRAS", "Panitumumab" ], 11.008924, [ [ "Manuel Valladares-Ayerbes, Maria José Safont, Encarnación González Flores, Pilar García-Alfonso, Enrique Aranda, Ana-Maria López Muñoz, Esther Falcó Ferrer, Luís Cirera Nogueras, Nuria Rodríguez-Salas, Jorge Aparicio, Marta Llanos Muñoz, Paola Patricia Pimentel Cáceres, Oscar Alfredo Castillo Trujillo, Rosario Vidal Tocino, Mercedes Salgado Fernández, Antonieta Salud-Salvia, Bartomeu Massuti Sureda, Rocio Garcia-Carbonero, Maria Ángeles Vicente Conesa, Ariadna Lloansí Vila, (2024). Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2640-2651. https://doi.org/10.1007/s12094-024-03487-4 PMID: 38642257", "38642257" ], [ "Gozde Kavgaci, Omer Dizdar, Suayib Yalcin (2024). Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer. Anti-cancer drugs, 459-461. https://doi.org/10.1097/CAD.0000000000001587 PMID: 38451823", "38451823" ], [ "Kohei Shitara, Kei Muro, Jun Watanabe, Kentaro Yamazaki, Hisatsugu Ohori, Manabu Shiozawa, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Ikuo Mori, Kazunori Yamanaka, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Riu Yamashita, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino (2024). Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nature medicine, 730-739. https://doi.org/10.1038/s41591-023-02791-w PMID: 38347302", "38347302" ], [ "Simon Haefliger, Katharina Marston, Ilaria Alborelli, Edouard-Jean Stauffer, Mathias Gugger, Philip M Jermann, Sylvia Hoeller, Luigi Tornillo, Luigi M Terracciano, Michel Bihl, Matthias S Matter (2023). Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics. Pathobiology : journal of immunopathology, molecular and cellular biology, 166-175. https://doi.org/10.1159/000526117 PMID: 36202073", "36202073" ], [ "Ahmet Rencuzogullari, Atil Bisgin, Kivilcim Eren Erdogan, Serdar Gumus, Orcun Yalav, Ibrahim Boga, Ozge Sonmezler, Ismail Cem Eray (2023). Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel. Annali italiani di chirurgia, 605-611. PMID: 38131395", "38131395" ], [ "Chengren Zhang, Lili Liu, Yaochun Lv, Jingjing Li, Cong Cao, Jiyong Lu, Shuai Wang, Binbin Du, Xiongfei Yang (2022). Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis. Expert review of anticancer therapy, 1333-1347. https://doi.org/10.1080/14737140.2022.2147512 PMID: 36374121", "36374121" ], [ "Anyue Yin, Johan G C van Hasselt, Henk-Jan Guchelaar, Lena E Friberg, Dirk Jan A R Moes (2022). Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance. Scientific reports, 4206. https://doi.org/10.1038/s41598-022-08012-7 PMID: 35273301", "35273301" ], [ "Yifei Sun, Xuming He, Jianhua Hu (2022). AN OMNIBUS TEST FOR DETECTION OF SUBGROUP TREATMENT EFFECTS VIA DATA PARTITIONING. The annals of applied statistics, 2266-2278. https://doi.org/10.1214/21-AOAS1589 PMID: 37521002", "37521002" ], [ "Huu Thinh Nguyen, Trieu Vu Nguyen, Van-Anh Nguyen Hoang, Duc Huy Tran, Ngoc An Le Trinh, Minh Triet Le, Tuan-Anh Nguyen Tran, Thanh Huyen Pham, Thi Cuc Dinh, Tien Sy Nguyen, Ky Cuong Nguyen The, Hoa Mai, Minh Tuan Chu, Dinh Hoang Pham, Xuan Chi Nguyen, Thien My Ngo Ha, Duy Sinh Nguyen, Du Quyen Nguyen, Y-Thanh Lu, Thanh Thuy Do Thi, Dinh Kiet Truong, Quynh Tho Nguyen, Hoai-Nghia Nguyen, Hoa Giang, Lan N Tu (2022). Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients. Frontiers in oncology, 1069296. https://doi.org/10.3389/fonc.2022.1069296 PMID: 36578946", "36578946" ], [ "Samuel A Jacobs, James J Lee, Thomas J George, James L Wade, Philip J Stella, Ding Wang, Ashwin R Sama, Fanny Piette, Katherine L Pogue-Geile, Rim S Kim, Patrick G Gavin, Corey Lipchik, Huichen Feng, Ying Wang, Melanie Finnigan, Brian F Kiesel, Jan H Beumer, Norman Wolmark, Peter C Lucas, Carmen J Allegra, Ashok Srinivasan (2021). Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 1612-1622. https://doi.org/10.1158/1078-0432.CCR-20-1831 PMID: 33203645", "33203645" ] ] ], [ [ "KRAS", "Oxaliplatin" ], 10.5778, [ [ "Victoria Chung, Jonathan D Mizrahi, Shubham Pant (2024). Novel Therapies for Pancreatic Cancer. JCO oncology practice, OP2400279. https://doi.org/10.1200/OP.24.00279 PMID: 39591547", "39591547" ], [ "Juhi Mody, Mandana Kamgar (2024). Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review. Case reports in oncology, 399-406. https://doi.org/10.1159/000536552 PMID: 38435447", "38435447" ], [ "T Q Zhang, Y Xu (2024). [A case of familial adenomatous polyposis in an adult male with Lynch-like syndrome]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 1168-1171. https://doi.org/10.3760/cma.j.cn441530-20231106-00163 PMID: 39572183", "39572183" ], [ "Huiling Song, Haosheng Li, Xiaonan Shen, Kuai Liu, Haoran Feng, Jiahua Cui, Wei Wei, Xiaolu Sun, Qiong Fan, Wei Bao, Haiyan Zhou, Liheng Qian, Huizhen Nie, Xi Cheng, Zixiu Du (2024). A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma. Acta biomaterialia, 456-471. https://doi.org/10.1016/j.actbio.2024.01.047 PMID: 38331131", "38331131" ], [ "Sora Kang, Myung-Won Lee, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Deog-Yeon Jo, Jung Sun Kim, Jung Hye Kwon, Ji-Yeon Kim, Kyung-Ha Lee, Hyewon Ryu (2023). Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAFV600E mutation status. Journal of cancer research and clinical oncology, 7819-7829. https://doi.org/10.1007/s00432-023-04720-3 PMID: 37031435", "37031435" ], [ "Florinda A Santos, Rui Manuel Reis, Lucas C Barroti, Allan A L Pereira, Marcus M Matsushita, Ana Carolina de Carvalho, José Guilherme Datorre, Gustavo N Berardinelli, Raphael L C Araujo (2023). Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer. Journal of gastrointestinal cancer. https://doi.org/10.1007/s12029-023-00964-x PMID: 37608030", "37608030" ], [ "Wai-Hung Leung, Jing-Wen Shih, Jian-Syun Chen, Ntlotlang Mokgautsi, Po-Li Wei, Yan-Jiun Huang (2022). Preclinical Identification of Sulfasalazine's Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines. https://doi.org/10.3390/biomedicines10020377 PMID: 35203586", "35203586" ], [ "Arata Nishimoto (2022). Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World journal of gastroenterology, 3637-3643. https://doi.org/10.3748/wjg.v28.i28.3637 PMID: 36161054", "36161054" ], [ "Min Shi, Hong Yuan, Jun Ji, Shouwei Zhang, Qingyuan Li, Yawei Chen, Xiaoli Gong, Zhenggang Zhu, Jun Zhang (2022). Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer. Therapeutic advances in medical oncology, 17588359211070643. https://doi.org/10.1177/17588359211070643 PMID: 35096147", "35096147" ], [ "Y Sunakawa, H Satake, J Usher, Y Jaimes, Y Miyamoto, M Nakamura, M Kataoka, M Shiozawa, A Takagane, T Terazawa, T Watanabe, K Ishiguro, C Tanaka, M Takeuchi, M Fujii, K Danenberg, P V Danenberg, H-J Lenz, T Sekikawa, W Ichikawa (2022). Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). ESMO open, 100512. https://doi.org/10.1016/j.esmoop.2022.100512 PMID: 35688061", "35688061" ] ] ], [ [ "KRAS", "Irinotecan" ], 12.809579999999999, [ [ "Victoria Chung, Jonathan D Mizrahi, Shubham Pant (2024). Novel Therapies for Pancreatic Cancer. JCO oncology practice, OP2400279. https://doi.org/10.1200/OP.24.00279 PMID: 39591547", "39591547" ], [ "Juhi Mody, Mandana Kamgar (2024). Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review. Case reports in oncology, 399-406. https://doi.org/10.1159/000536552 PMID: 38435447", "38435447" ], [ "Sophie Laroche, Olivier Scatton, Frederic Charlotte, Jean-Baptiste Bachet, Chetana Lim, David Fuks, Claire Goumard (2024). Prognosis of a Heterogeneous TRG Pathological Response to Neoadjuvant Chemotherapy in Patients who Undergo Resection for Colorectal Liver Metastases. Annals of surgical oncology, 4436-4444. https://doi.org/10.1245/s10434-024-15196-x PMID: 38549003", "38549003" ], [ "Keun-Wook Lee, Sae-Won Han, Tae Won Kim, Joong Bae Ahn, Ji Yeon Baek, Sang Hee Cho, Howard Lee, Jin Won Kim, Ji-Won Kim, Tae-You Kim, Yong Sang Hong, Seung-Hoon Beom, Yongjun Cha, Yoonjung Choi, Seonhui Kim, Yung-Jue Bang (2023). A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer. Cancer research and treatment. https://doi.org/10.4143/crt.2023.1117 PMID: 38062706", "38062706" ], [ "Tamotsu Sagawa, Yasushi Sato, Masahiro Hirakawa, Kyoko Hamaguchi, Fumito Tamura, Hiroyuki Nagashima, Koshi Fujikawa, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama (2023). Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer. Frontiers in oncology, 1203296. https://doi.org/10.3389/fonc.2023.1203296 PMID: 37434969", "37434969" ], [ "Florinda A Santos, Rui Manuel Reis, Lucas C Barroti, Allan A L Pereira, Marcus M Matsushita, Ana Carolina de Carvalho, José Guilherme Datorre, Gustavo N Berardinelli, Raphael L C Araujo (2023). Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer. Journal of gastrointestinal cancer. https://doi.org/10.1007/s12029-023-00964-x PMID: 37608030", "37608030" ], [ "Pilar García-Alfonso, Astrid Lièvre, Fotios Loupakis, Abir Tadmouri, Sadya Khan, Leticia Barcena, Sebastian Stintzing (2022). Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer. Critical reviews in oncology/hematology, 103646. https://doi.org/10.1016/j.critrevonc.2022.103646 PMID: 35344913", "35344913" ], [ "Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, Ludwig Fischer von Weikersthal, Markus M Lerch, Thomas Decker, Alexander Kiani, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Heinz-Gert Höffkes, Markus Moehler, Alena Britta Gesenhues, Sebastian Theurich, Marlies Michl, Dominik P Modest, Hana Algül, Sebastian Stintzing, Volker Heinemann, Julian W Holch (2022). Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). International journal of cancer, 112-123. https://doi.org/10.1002/ijc.33775 PMID: 34431518", "34431518" ], [ "Arata Nishimoto (2022). Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World journal of gastroenterology, 3637-3643. https://doi.org/10.3748/wjg.v28.i28.3637 PMID: 36161054", "36161054" ], [ "Min Shi, Hong Yuan, Jun Ji, Shouwei Zhang, Qingyuan Li, Yawei Chen, Xiaoli Gong, Zhenggang Zhu, Jun Zhang (2022). Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer. Therapeutic advances in medical oncology, 17588359211070643. https://doi.org/10.1177/17588359211070643 PMID: 35096147", "35096147" ] ] ], [ [ "DOT1L", "venetoclax" ], 0.38474659, [ [ "Caner Saygin, Hetty E Carraway (2017). Emerging therapies for acute myeloid leukemia. Journal of hematology & oncology, 93. https://doi.org/10.1186/s13045-017-0463-6 PMID: 28420416", "28420416" ], [ "Danielle Shafer, Steven Grant (2016). Update on rational targeted therapy in AML. Blood reviews, 275-83. PMID: 26972558", "26972558" ], [ "Juliana M Benito, Laura Godfrey, Kensuke Kojima, Leah Hogdal, Mark Wunderlich, Huimin Geng, Isabel Marzo, Karine G Harutyunyan, Leonard Golfman, Phillip North, Jon Kerry, Erica Ballabio, Triona Ní Chonghaile, Oscar Gonzalo, Yihua Qiu, Irmela Jeremias, LaKiesha Debose, Eric O'Brien, Helen Ma, Ping Zhou, Rodrigo Jacamo, Eugene Park, Kevin R Coombes, Nianxiang Zhang, Deborah A Thomas, Susan O'Brien, Hagop M Kantarjian, Joel D Leverson, Steven M Kornblau, Michael Andreeff, Markus Müschen, Patrick A Zweidler-McKay, James C Mulloy, Anthony Letai, Thomas A Milne, Marina Konopleva (2015). MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell reports, 2715-27. PMID: 26711339", "26711339" ] ] ], [ [ "PIK3CA", "NVP-BKM120" ], 4.5634285000000006, [ [ "Sandeep Kumar, Shalmoli Bhattacharyya, Ashim Das, Gurpreet Singh, Amanjit Bal (2022). In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines. Breast disease, 241-247. https://doi.org/10.3233/BD-210066 PMID: 35431224", "35431224" ], [ "Yixuan Ma, Sina Sender, Anett Sekora, Weibo Kong, Peter Bauer, Najim Ameziane, Ruslan Al-Ali, Susann Krake, Mandy Radefeldt, Frank Ulrich Weiss, Markus M Lerch, Alisha Parveen, Dietmar Zechner, Christian Junghanss, Hugo Murua Escobar (2022). The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. International journal of molecular sciences. https://doi.org/10.3390/ijms23084295 PMID: 35457111", "35457111" ], [ "Sun Min Lim, San-Duk Yang, Sangbin Lim, Seong Gu Heo, Stetson Daniel, Aleksandra Markovets, Rafati Minoo, Kyoung-Ho Pyo, Mi Ran Yun, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho (2022). Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. Therapeutic advances in medical oncology, 17588359221079125. https://doi.org/10.1177/17588359221079125 PMID: 35251316", "35251316" ], [ "Ge-Ping Qu, Min Shi, Dan Wang, Jiong-He Wu, Peng Wang, Mei-Liang Gong, Zhi-Jian Zhang (2021). Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds. BMC pulmonary medicine, 208. https://doi.org/10.1186/s12890-021-01571-x PMID: 34210314", "34210314" ], [ "Ariella B Hanker, Benjamin P Brown, Jens Meiler, Arnaldo Marín, Harikrishna S Jayanthan, Dan Ye, Chang-Ching Lin, Hiroaki Akamatsu, Kyung-Min Lee, Sumanta Chatterjee, Dhivya R Sudhan, Alberto Servetto, Monica Red Brewer, James P Koch, Jonathan H Sheehan, Jie He, Alshad S Lalani, Carlos L Arteaga (2021). Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer cell, 1099-1114.e8. https://doi.org/10.1016/j.ccell.2021.06.001 PMID: 34171264", "34171264" ], [ "Jinshan Xing, Jun Yang, Yingjiang Gu, Jingyan Yi (2021). Research update on the anticancer effects of buparlisib. Oncology letters, 266. https://doi.org/10.3892/ol.2021.12527 PMID: 33717263", "33717263" ], [ "Chi-Heng Wu, Chen-Yen Yang, Linlin Wang, Hua-Xin Gao, Taha Rakhshandehroo, Shervin Afghani, Laura Pincus, Ronald Balassanian, James Rubenstein, Ryan Gill, Sourav Bandyopadhyay, Frank McCormick, Mark Moasser, Weiyun Z Ai (2021). Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC. The Journal of investigative dermatology, 364-373. https://doi.org/10.1016/j.jid.2020.05.110 PMID: 32603749", "32603749" ], [ "Cristina Uribe-Alvarez, Sandra Lucía Guerrero-Rodríguez, Jennifer Rhodes, Alexa Cannon, Jonathan Chernoff, Daniela Araiza-Olivera (2021). Targeting effector pathways in RAC1P29S-driven malignant melanoma. Small GTPases, 273-281. https://doi.org/10.1080/21541248.2020.1728469 PMID: 32043900", "32043900" ], [ "Tong Zhao, Yuqin Tian, Xinjia Ding, Lin Liu, Bowen Tan, Bin Yang, Jianlin Wu, Ting Lei, Ruoyu Wang, Yan Ding (2021). Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report. OncoTargets and therapy, 2839-2845. https://doi.org/10.2147/OTT.S298697 PMID: 33953569", "33953569" ], [ "Dwan-Ying Chang, Wei-Li Ma, Yen-Shen Lu (2021). Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives. Therapeutics and clinical risk management, 193-207. https://doi.org/10.2147/TCRM.S251668 PMID: 33707948", "33707948" ] ] ], [ [ "DOT1L", "Histone-Lysine N-Methyltransferase" ], 4.0952684, [ [ "Ryan J Separovich, Nicola M Karakatsanis, Kelley Gao, David Fuh, Joshua J Hamey, Marc R Wilkins (2024). Proline-directed yeast and human MAP kinases phosphorylate the Dot1p/DOT1L histone H3K79 methyltransferase. The FEBS journal, 2590-2614. https://doi.org/10.1111/febs.17062 PMID: 38270553", "38270553" ], [ "Justin W Leung, Kyle M Miller (2024). DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1. Trends in pharmacological sciences, 955-957. https://doi.org/10.1016/j.tips.2024.09.008 PMID: 39389815", "39389815" ], [ "Bidyadhar Sethy, Zih-Yao Yu, Iin Narwanti, Richa Upadhyay, Mei-Jung Lai, Sung-Bau Lee, Jing-Ping Liou (2024). Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents. Bioorganic chemistry, 107771. https://doi.org/10.1016/j.bioorg.2024.107771 PMID: 39299178", "39299178" ], [ "Gabriele Ciceri, Arianna Baggiolini, Hyein S Cho, Meghana Kshirsagar, Silvia Benito-Kwiecinski, Ryan M Walsh, Kelly A Aromolaran, Alberto J Gonzalez-Hernandez, Hermany Munguba, So Yeon Koo, Nan Xu, Kaylin J Sevilla, Peter A Goldstein, Joshua Levitz, Christina S Leslie, Richard P Koche, Lorenz Studer (2024). An epigenetic barrier sets the timing of human neuronal maturation. Nature, 881-890. https://doi.org/10.1038/s41586-023-06984-8 PMID: 38297124", "38297124" ], [ "Yanhong Zong, Ming Zhao, Zhipeng Tang, Yanqing Tie, Kenan Peng, He Tan (2024). SALL4 mediates SHP2 inhibition in myocardial fibroblasts through the DOT1L/H3K79me2 signaling pathway to promote the progression of myocardial infarction. Scientific reports, 30938. https://doi.org/10.1038/s41598-024-81815-y PMID: 39730739", "39730739" ], [ "Xue Li, Pei Pei, Jinying Shen, Juan Yu, Fang Wang, Lei Wang, Changyun Liu, Shan Wang (2023). Folate deficiency reduced aberrant level of DOT1L-mediated histone H3K79 methylation causes disruptive SHH gene expression involved in neural tube defects. Epigenetics & chromatin, 50. https://doi.org/10.1186/s13072-023-00517-3 PMID: 38093377", "38093377" ], [ "Zelha Nil, Ashish R Deshwar, Yan Huang, Scott Barish, Xi Zhang, Sanaa Choufani, Polona Le Quesne Stabej, Ian Hayes, Patrick Yap, Chad Haldeman-Englert, Carolyn Wilson, Trine Prescott, Kristian Tveten, Arve Vøllo, Devon Haynes, Patricia G Wheeler, Jessica Zon, Cheryl Cytrynbaum, Rebekah Jobling, Moira Blyth, Siddharth Banka, Alexandra Afenjar, Cyril Mignot, Florence Robin-Renaldo, Boris Keren, Oguz Kanca, Xiao Mao, Daniel J Wegner, Kathleen Sisco, Marwan Shinawi, , Michael F Wangler, Rosanna Weksberg, Shinya Yamamoto, Gregory Costain, Hugo J Bellen (2023). Rare de novo gain-of-function missense variants in DOT1L are associated with developmental delay and congenital anomalies. American journal of human genetics, 1919-1937. https://doi.org/10.1016/j.ajhg.2023.09.009 PMID: 37827158", "37827158" ], [ "Wei Wei, Yibo Zhao, Yanfen Chai, Songtao Shou, Heng Jin (2023). A novel role of DOT1L in kidney diseases. Molecular biology reports, 5415-5423. https://doi.org/10.1007/s11033-023-08415-3 PMID: 37085741", "37085741" ], [ "Yi-Bin Yang, Cai-Yuan Wu, Xu-Yan Wang, Jia Deng, Wen-Jie Cao, Yun-Zhi Tang, Chao-Chao Wan, Zhi-Tian Chen, Wan-Yu Zhan, Hong Shan, Dong-Ming Kuang, Yuan Wei (2023). Targeting inflammatory macrophages rebuilds therapeutic efficacy of DOT1L inhibition in hepatocellular carcinoma. Molecular therapy : the journal of the American Society of Gene Therapy, 105-118. https://doi.org/10.1016/j.ymthe.2022.09.019 PMID: 36183166", "36183166" ], [ "Yanguang Hou, Yan Yuan, Yanze Li, Lei Wang, Juncheng Hu, Xiuheng Liu (2023). The role of histone methylation in renal cell cancer: an update. Molecular biology reports, 2735-2742. https://doi.org/10.1007/s11033-022-08124-3 PMID: 36575323", "36575323" ] ] ], [ [ "KRAS", "GUANOSINE-5'-DIPHOSPHATE" ], 2.7854799999999997 ], [ [ "DOT1L", "Permethrin" ], 0.70363074 ], [ [ "4URU The crystal structure of H-Ras and SOS in complex with ligands", "KRAS" ], 7.036307399999999 ], [ [ "PIK3CA", "Alpelisib" ], 16.200688, [ [ "Baoyu He, Qingli Bie, Rou Zhao, Yugang Yan, Guanjun Dong, Baogui Zhang, Sen Wang, Wenrong Xu, Dongxing Tian, Yujun Hao, Yanhua Zhang, Mingsheng Zhao, Huabao Xiong, Bin Zhang (2024). Arachidonic acid released by PIK3CA mutant tumor cells triggers malignant transformation of colonic epithelium by inducing chromatin remodeling. Cell reports. Medicine, 101510. https://doi.org/10.1016/j.xcrm.2024.101510 PMID: 38614093", "38614093" ], [ "Iseult M Browne, Alicia F C Okines (2024). Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer. Cancers. https://doi.org/10.3390/cancers16122259 PMID: 38927964", "38927964" ], [ "Tomás Reinert, Fernanda Orpinelli do Rego, Matheus Costa E Silva, Amanda Muniz Rodrigues, Fernanda Christtanini Koyama, Aline Coelho Gonçalves, Maiane Maria Pauletto, Leandro Jonata de Carvalho Oliveira, Cristiano Augusto Andrade de Resende, Luciana Castro Garcia Landeiro, Carlos Henrique Barrios, Max Senna Mano, Rodrigo Dienstmann (2024). The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients. Frontiers in oncology, 1372947. https://doi.org/10.3389/fonc.2024.1372947 PMID: 38952553", "38952553" ], [ "Benjamin Edmonds, Jacqueline P Ngo, Aran Groves, Beck Reyes, Rolanda A Gott, Dennis J Chia, Hilda Mirbaha, Shino Magaki, Negar Khanlou, Stacy L Pineles, Noriko Salamon, Rachel M Thompson, Maya Newman, Rajsekar R Rajaraman, Shaun A Hussain, Aria Fallah, Bianca Russell, Hiroki Nariai (2024). Multi-disciplinary team approach for pediatric hemimegalencephaly: Insights from a single institutional case series. Epilepsia open, 2510-2517. https://doi.org/10.1002/epi4.13079 PMID: 39442533", "39442533" ], [ "Lukas Bissegger, Theodora A Constantin, Erhan Keles, Luka Raguž, Isobel Barlow-Busch, Clara Orbegozo, Thorsten Schaefer, Valentina Borlandelli, Thomas Bohnacker, Rohitha Sriramaratnam, Alexander Schäfer, Matthias Gstaiger, John E Burke, Chiara Borsari, Matthias P Wymann (2024). Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signaling. Chemical science, 20274-20291. https://doi.org/10.1039/d4sc05459h PMID: 39568927", "39568927" ], [ "Muhammad Shafiq, Zaid Anis Sherwani, Mamona Mushtaq, Mohammad Nur-E-Alam, Aftab Ahmad, Zaheer Ul-Haq (2024). A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kα inhibitors. Molecular diversity, 1907-1924. https://doi.org/10.1007/s11030-023-10799-0 PMID: 38305819", "38305819" ], [ "Hon Yan Kelvin Yip, Sung-Young Shin, Annabel Chee, Ching-Seng Ang, Fernando J Rossello, Lee Hwa Wong, Lan K Nguyen, Antonella Papa (2024). Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer. NPJ precision oncology, 20. https://doi.org/10.1038/s41698-024-00496-y PMID: 38273040", "38273040" ], [ "Junna Yamaguchi, Pierre Isnard, Noémie Robil, Pierre de la Grange, Clément Hoguin, Alain Schmitt, Aurélie Hummel, Jérôme Megret, Nicolas Goudin, Marine Luka, Mickaël M Ménager, Cécile Masson, Mohammed Zarhrate, Christine Bôle-Feysot, Michalina Janiszewska, Kornelia Polyak, Julien Dairou, Sara Baldassari, Stéphanie Baulac, Christine Broissand, Christophe Legendre, Fabiola Terzi, Guillaume Canaud (2024). PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis. The Journal of clinical investigation. PMID: 38842935", "38842935" ], [ "Samar I Faggal, Yara El-Dash, Amr Sonousi, Amr M Abdou, Rasha A Hassan (2024). Design, synthesis, and biological evaluation of novel thiazole derivatives as PI3K/mTOR dual inhibitors. RSC medicinal chemistry. https://doi.org/10.1039/d4md00462k PMID: 39345714", "39345714" ], [ "Amy T Ku, Adelaide I J Young, Ahmed Atef Ibrahim, Wen Bu, Weiyu Jiang, Meng Lin, Laterrica C Williams, Bryant Lee McCue, George Miles, Chandandeep Nagi, Fariba Behbod, Yi Li (2023). Short-term PI3K Inhibition Prevents Breast Cancer in Preclinical Models. Cancer prevention research (Philadelphia, Pa.), 65-73. https://doi.org/10.1158/1940-6207.CAPR-22-0275 PMID: 36343340", "36343340" ] ] ], [ [ "SOS1", "sotorasib" ], 11.856758000000001, [ [ "Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler (2024). Development of PROTACS degrading KRAS and SOS1. Oncology research, 1257-1264. https://doi.org/10.32604/or.2024.051653 PMID: 39055890", "39055890" ], [ "Yan Lv, Zixuan Yang, Yiming Chen, Xuepei Ma, Mengqi Guo, Chengwei Zhang, Xiaolin Jiang, Chengli Wang, Zhuoyue Li, Zhengfu Tai, Xiao Wang, Siqi Zhang, Shumin Ma, Chong Qin (2024). A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor. Journal of medicinal chemistry, 2487-2511. https://doi.org/10.1021/acs.jmedchem.3c01598 PMID: 38316747", "38316747" ], [ "Sandra Stickler, Barbara Rath, Gerhard Hamilton (2024). Targeting KRAS in pancreatic cancer. Oncology research, 799-805. https://doi.org/10.32604/or.2024.045356 PMID: 38686056", "38686056" ], [ "Fei Xiao, Kailiang Wang, Xinjuan Wang, Huijuan Li, Zhilong Hu, Xiaoming Ren, Wei Huang, Teng Feng, Lili Yao, Jing Lin, Chunlai Li, Zhuanzhuan Zhang, Liufeng Mei, Xiaotian Zhu, Wenge Zhong, Zhi Xie (2024). Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers. Molecular cancer therapeutics, 1703-1716. https://doi.org/10.1158/1535-7163.MCT-24-0049 PMID: 39087485", "39087485" ], [ "Yanguo Shang, Shengnan Fu, Qingjing Hao, Hanjie Ying, Jinxin Wang, Tao Shen (2024). Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions. Bioorganic chemistry, 107092. https://doi.org/10.1016/j.bioorg.2023.107092 PMID: 38271825", "38271825" ], [ "Xinchao Zhao, Yawen Zheng, Yufeng Wang, Mingyan Zhang, Zhilin Dong, Yanan Liu, Meili Sun (2024). The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer. OncoTargets and therapy, 1041-1057. https://doi.org/10.2147/OTT.S484209 PMID: 39564454", "39564454" ], [ "Gerhard Hamilton, Sandra Stickler, Barbara Rath (2023). Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras. Current pharmaceutical design, 1741-1746. https://doi.org/10.2174/1381612829666230418114520 PMID: 37073657", "37073657" ], [ "Yi Chen, Qiu-Pei Liu, Hua Xie, Jian Ding (2023). From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Acta pharmacologica Sinica. https://doi.org/10.1038/s41401-023-01194-4 PMID: 38049578", "38049578" ], [ "Na Li, Chen-Fu Liu, Wen Zhang, Guo-Wu Rao (2023). A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C). Current medicinal chemistry. https://doi.org/10.2174/0109298673258913231019113814 PMID: 37936461", "37936461" ], [ "Sajid Khan, Vivekananda Budamagunta, Daohong Zhou (2023). Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies. Advances in cancer research, 145-184. https://doi.org/10.1016/bs.acr.2023.02.004 PMID: 37268395", "37268395" ] ] ], [ [ "SOS1", "KRAS" ], 104.24673600000001, [ [ "Robert J Norgard, Pratha Budhani, Sarah A O'Brien, Youli Xia, Jessica N Egan, Brianna Flynn, Joshua R Tagore, Joseph Seco, Gregory W Peet, Ania Mikucka, Ruby Wasti, Li-Chuan Chan, Melanie Hinkel, Sandra Martinez-Morilla, Jeanine Pignatelli, Francesca Trapani, Emily Corse, Di Feng, Kaja Kostyrko, Marco H Hofmann, Kang Liu, Abhishek S Kashyap (2024). Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response. Cancer research communications, 1548-1560. https://doi.org/10.1158/2767-9764.CRC-24-0172 PMID: 38727236", "38727236" ], [ "Christopher R Smith, Dan Chen, James G Christensen, René Coulombe, James Féthière, Robin J Gunn, Johan Hollander, Benjamin Jones, John M Ketcham, Shilpi Khare, Jon Kuehler, J David Lawson, Matthew A Marx, Peter Olson, Kelly E Pearson, Cynthia Ren, Denise Tsagris, Thirumalaiselvi Ulaganathan, Inge Van't Veer, Xiaolun Wang, Anthony Ivetac (2024). Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography. Journal of medicinal chemistry, 774-781. https://doi.org/10.1021/acs.jmedchem.3c02140 PMID: 38156904", "38156904" ], [ "Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler (2024). Development of PROTACS degrading KRAS and SOS1. Oncology research, 1257-1264. https://doi.org/10.32604/or.2024.051653 PMID: 39055890", "39055890" ], [ "Venu Thatikonda, Hengyu Lyu, Sabine Jurado, Kaja Kostyrko, Christopher A Bristow, Christoph Albrecht, Donat Alpar, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A Machado, Thomas Madensky, Ethan D Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M Molkentine, Philipp A Jaeger, David H Peng, Robyn L Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Scott Kopetz, Christopher P Vellano, Mark Petronczki, Norbert Kraut, Timothy P Heffernan, Joseph R Marszalek, Mark Pearson, Irene C Waizenegger, Marco H Hofmann (2024). Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance. Nature cancer, 1352-1370. https://doi.org/10.1038/s43018-024-00800-6 PMID: 39103541", "39103541" ], [ "Yan Lv, Zixuan Yang, Yiming Chen, Xuepei Ma, Mengqi Guo, Chengwei Zhang, Xiaolin Jiang, Chengli Wang, Zhuoyue Li, Zhengfu Tai, Xiao Wang, Siqi Zhang, Shumin Ma, Chong Qin (2024). A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor. Journal of medicinal chemistry, 2487-2511. https://doi.org/10.1021/acs.jmedchem.3c01598 PMID: 38316747", "38316747" ], [ "Guizhen Zhou, Chuan Zhou, Xinyi Ma, Jiahang Xu, Zehui Zhou, Tianfeng Xu, Mingyue Zheng, Sulin Zhang (2024). An updated patent review of SOS1 inhibitors (2022-present). Expert opinion on therapeutic patents, 1199-1213. https://doi.org/10.1080/13543776.2024.2419825 PMID: 39435474", "39435474" ], [ "Zheyao Hu, Jordi Martí (2024). Unraveling atomic-scale mechanisms of GDP extraction catalyzed by SOS1 in KRAS-G12 and KRAS-D12 oncogenes. Computers in biology and medicine, 109599. https://doi.org/10.1016/j.compbiomed.2024.109599 PMID: 39731920", "39731920" ], [ "Zhuoyuan Zhang, Dan Liu, Rui Lv, Haoyan Zhao, Tianjing Li, Yutao Huang, Zhicheng Tian, Xiangyu Gao, Peng Luo, Xin Li (2024). FBL Promotes LPS-Induced Neuroinflammation by Activating the NF-κB Signaling Pathway. Journal of inflammation research, 2217-2231. https://doi.org/10.2147/JIR.S451049 PMID: 38623466", "38623466" ], [ "Yi Zeng, Chenyang Huang, Qiangqiang Hou, Wenhua Jiang, Jiaqi Cheng, Xiaoxing Wu (2024). Design, synthesis, and evaluation of dual son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR) inhibitors for the treatment of cancers. Bioorganic chemistry, 107833. https://doi.org/10.1016/j.bioorg.2024.107833 PMID: 39357170", "39357170" ], [ "Brianna R Daley, Heidi M Vieira, Chaitra Rao, Jacob M Hughes, Zaria M Beckley, Dianna H Huisman, Deepan Chatterjee, Nancy E Sealover, Katherine Cox, James W Askew, Robert A Svoboda, Kurt W Fisher, Robert E Lewis, Robert L Kortum (2023). SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status. Proceedings of the National Academy of Sciences of the United States of America, e2313137120. https://doi.org/10.1073/pnas.2313137120 PMID: 37972068", "37972068" ] ] ], [ [ "SOS1", "adagrasib" ], 23.571527, [ [ "Venu Thatikonda, Hengyu Lyu, Sabine Jurado, Kaja Kostyrko, Christopher A Bristow, Christoph Albrecht, Donat Alpar, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A Machado, Thomas Madensky, Ethan D Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M Molkentine, Philipp A Jaeger, David H Peng, Robyn L Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Scott Kopetz, Christopher P Vellano, Mark Petronczki, Norbert Kraut, Timothy P Heffernan, Joseph R Marszalek, Mark Pearson, Irene C Waizenegger, Marco H Hofmann (2024). Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance. Nature cancer, 1352-1370. https://doi.org/10.1038/s43018-024-00800-6 PMID: 39103541", "39103541" ], [ "Sandra Stickler, Barbara Rath, Gerhard Hamilton (2024). Targeting KRAS in pancreatic cancer. Oncology research, 799-805. https://doi.org/10.32604/or.2024.045356 PMID: 38686056", "38686056" ], [ "Fei Xiao, Kailiang Wang, Xinjuan Wang, Huijuan Li, Zhilong Hu, Xiaoming Ren, Wei Huang, Teng Feng, Lili Yao, Jing Lin, Chunlai Li, Zhuanzhuan Zhang, Liufeng Mei, Xiaotian Zhu, Wenge Zhong, Zhi Xie (2024). Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers. Molecular cancer therapeutics, 1703-1716. https://doi.org/10.1158/1535-7163.MCT-24-0049 PMID: 39087485", "39087485" ], [ "Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, Lars D Engstrom, Jade Laguer, Andrew Calinisan, Allan Hebbert, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, John M Ketcham, Anthony Ivetac, Christopher R Smith, J David Lawson, Lisa Rahbaek, Jeffrey Clarine, Natalie Nguyen, Barbara Saechao, Cody Parker, Adam J Elliott, Darin Vanderpool, Leo He, Laura D Hover, Julio Fernandez-Banet, Silvia Coma, Jonathan A Pachter, Jill Hallin, Matthew A Marx, David M Briere, James G Christensen, Peter Olson, Jacob Haling, Shilpi Khare (2024). The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading. Molecular cancer therapeutics, 1418-1430. https://doi.org/10.1158/1535-7163.MCT-23-0870 PMID: 38904222", "38904222" ], [ "Yanguo Shang, Shengnan Fu, Qingjing Hao, Hanjie Ying, Jinxin Wang, Tao Shen (2024). Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions. Bioorganic chemistry, 107092. https://doi.org/10.1016/j.bioorg.2023.107092 PMID: 38271825", "38271825" ], [ "Xinchao Zhao, Yawen Zheng, Yufeng Wang, Mingyan Zhang, Zhilin Dong, Yanan Liu, Meili Sun (2024). The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer. OncoTargets and therapy, 1041-1057. https://doi.org/10.2147/OTT.S484209 PMID: 39564454", "39564454" ], [ "Gerhard Hamilton, Sandra Stickler, Barbara Rath (2023). Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras. Current pharmaceutical design, 1741-1746. https://doi.org/10.2174/1381612829666230418114520 PMID: 37073657", "37073657" ], [ "Yi Chen, Qiu-Pei Liu, Hua Xie, Jian Ding (2023). From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Acta pharmacologica Sinica. https://doi.org/10.1038/s41401-023-01194-4 PMID: 38049578", "38049578" ], [ "Na Li, Chen-Fu Liu, Wen Zhang, Guo-Wu Rao (2023). A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C). Current medicinal chemistry. https://doi.org/10.2174/0109298673258913231019113814 PMID: 37936461", "37936461" ], [ "Venu Thatikonda, Hengyu Lu, Sabine Jurado, Kaja Kostyrko, Christopher A Bristow, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Simone Lieb, Astrid Jeschko, Annette A Machado, Ethan D Marszalek, Mikhila Mahendra, Philipp A Jaeger, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Scott Kopetz, Christopher P Vellano, Mark Petronczki, Norbert Kraut, Timothy P Heffernan, Joseph R Marszalek, Mark Pearson, Irene Waizenegger, Marco H Hofmann (2023). Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2023.01.23.525210 PMID: 36747713", "36747713" ] ] ], [ [ "SOS1", "Osteocalcin" ], 11.727179000000001 ], [ [ "KRAS", "PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER" ], 3.0099028 ], [ [ "PIK3CA", "Fulvestrant" ], 15.312574000000001, [ [ "Adrish Sen, Salmaan Khan, Stefano Rossetti, Aaron Broege, Ian MacNeil, Ann DeLaForest, Jhomary Molden, Laura Davis, Charles Iversrud, Megan Seibel, Ross Kopher, Stephen Schulz, Lance Laing (2025). Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. Molecular oncology, 225-247. https://doi.org/10.1002/1878-0261.13703 PMID: 39092562", "39092562" ], [ "Victor Heurtier, Alexandre de Nonneville (2024). [Capivasertib in combination with fulvestrant in locally advanced or metastatic RH+ HER2- breast cancer with PIK3CA, AKT1 or PTEN alteration, after first-line hormonal therapy]. Bulletin du cancer, 997-998. https://doi.org/10.1016/j.bulcan.2024.08.010 PMID: 39317592", "39317592" ], [ "Eriko Tokunaga, Hiroji Iwata, Mitsuya Itoh, Tetsuhiko Taira, Tatsuya Toyama, Toshiro Mizuno, Akihiko Osaki, Yasuhiro Yanagita, Seigo Nakamura, Rikiya Nakamura, Tomoko Sambe, Toshiaki Ozaki, Gaia Schiavon, Sacha J Howell, Masakazu Toi (2024). Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial. Breast cancer (Tokyo, Japan). https://doi.org/10.1007/s12282-024-01640-z PMID: 39379782", "39379782" ], [ "Robert Roskoski (2024). Targeted and cytotoxic inhibitors used in the treatment of breast cancer. Pharmacological research, 107534. https://doi.org/10.1016/j.phrs.2024.107534 PMID: 39631485", "39631485" ], [ "Asma Dilawari, James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K Ricks, Timothy Schaefer, Sreedevi Avasarala, Francisca Reyes Turcu, Anand Pathak, Shyam Kalavar, Vishal Bhatnagar, Justin Collazo, Nam Atiqur Rahman, Bronwyn Mixter, Shenghui Tang, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani (2024). US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 4103-4113. https://doi.org/10.1200/JCO.24.00427 PMID: 39159418", "39159418" ], [ "Li Zhang, Yanlei Zheng, Gao Chen, Fang Zhao, Shi Li (2024). Case report: Phosphoinositide 3-kinase inhibitor with fulvestrant in a patient with ER+/HER2- metastatic breast carcinoma induced fatal arrhythmias: a preventable event? Frontiers in oncology, 1331472. https://doi.org/10.3389/fonc.2024.1331472 PMID: 38952547", "38952547" ], [ "Nicholas C Turner, Mafalda Oliveira, Sacha J Howell, Florence Dalenc, Javier Cortés, Henry L Gomez, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Yeon Hee Park, Joo-Hyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S Rugo (2024). A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer. Future oncology (London, England), 2901-2913. https://doi.org/10.1080/14796694.2024.2390791 PMID: 39283299", "39283299" ], [ "Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, Rene P Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist (2024). mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors. Cancer research communications, 2058-2074. https://doi.org/10.1158/2767-9764.CRC-24-0113 PMID: 38954770", "38954770" ], [ "Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park, Rinath Jeselsohn, Umut Demirci, Miguel Martin, Rachel M Layman, Sara A Hurvitz, Sarah Sammons, Peter A Kaufman, Montserrat Muñoz, Jiun-I Lai, Holly Knoderer, Cynthia Sandoval, Aarti R Chawla, Bastien Nguyen, Yanhong Zhou, Elizabeth Ravenberg, Lacey M Litchfield, Lillian Smyth, Seth A Wander (2024). Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2402086. https://doi.org/10.1200/JCO-24-02086 PMID: 39693591", "39693591" ], [ "Mafalda Oliveira, Hope S Rugo, Sacha J Howell, Florence Dalenc, Javier Cortes, Henry L Gomez, Xichun Hu, Masakazu Toi, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Zbigniew Nowecki, Yeon Hee Park, Joo Hyuk Sohn, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Marta Fulford, Haylee Andrews, Ian Wadsworth, Celina D'Cruz, Nicholas C Turner, (2024). Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 1231-1244. https://doi.org/10.1016/S1470-2045(24)00373-5 PMID: 39214106", "39214106" ] ] ], [ [ "4URU The crystal structure of H-Ras and SOS in complex with ligands", "5DTM Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]" ], 306.28633 ], [ [ "4URU The crystal structure of H-Ras and SOS in complex with ligands", "SOS1" ], 7.036307399999999 ], [ [ "PIK3CA", "MK 2206" ], 3.343206, [ [ "Daniel J Smit, Helena Brauer, Stefan Horn, Gökhan Yigit, Marie-Therese Haider, Vivian Pogenberg, Udo Schumacher, Klaus Pantel, Manfred Jücker (2024). Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells. Cellular signalling, 111270. https://doi.org/10.1016/j.cellsig.2024.111270 PMID: 38909932", "38909932" ], [ "Yixuan Ma, Sina Sender, Anett Sekora, Weibo Kong, Peter Bauer, Najim Ameziane, Ruslan Al-Ali, Susann Krake, Mandy Radefeldt, Frank Ulrich Weiss, Markus M Lerch, Alisha Parveen, Dietmar Zechner, Christian Junghanss, Hugo Murua Escobar (2022). The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. International journal of molecular sciences. https://doi.org/10.3390/ijms23084295 PMID: 35457111", "35457111" ], [ "Supharada Tessiri, Anchalee Techasen, Sarinya Kongpetch, Achira Namjan, Watcharin Loilome, Waraporn Chan-On, Raynoo Thanan, Apinya Jusakul (2022). Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma. PeerJ, e12750. https://doi.org/10.7717/peerj.12750 PMID: 35070505", "35070505" ], [ "Shuhang Liang, Hongrui Guo, Kun Ma, Xianying Li, Dehai Wu, Yiqi Wang, Wei Wang, Shugeng Zhang, Yifeng Cui, Yufeng Liu, Linmao Sun, Bo Zhang, Mengyang Xin, Ning Zhang, Huanran Zhou, Yao Liu, Jiabei Wang, Lianxin Liu (2021). A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression. Cancer research, 5889-5903. https://doi.org/10.1158/0008-5472.CAN-21-1538 PMID: 34580062", "34580062" ], [ "Tong Zhao, Yuqin Tian, Xinjia Ding, Lin Liu, Bowen Tan, Bin Yang, Jianlin Wu, Ting Lei, Ruoyu Wang, Yan Ding (2021). Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report. OncoTargets and therapy, 2839-2845. https://doi.org/10.2147/OTT.S298697 PMID: 33953569", "33953569" ], [ "Ruyue Xu, Yinci Zhang, Amin Li, Yongfang Ma, Wenpeng Cai, Li Song, Yinghai Xie, Shuping Zhou, Weiya Cao, Xiaolong Tang (2021). LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway. Molecular medicine reports. PMID: 33982772", "33982772" ], [ "Jeremy Johnson, Zeta Chow, Dana Napier, Eun Lee, Heidi L Weiss, B Mark Evers, Piotr Rychahou (2020). Targeting PI3K and AMPKα Signaling Alone or in Combination to Enhance Radiosensitivity of Triple Negative Breast Cancer. Cells. https://doi.org/10.3390/cells9051253 PMID: 32438621", "32438621" ], [ "Andrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, Weixiu Luo, Russell R Broaddus, Vicky Makker, Ronny Drapkin, Joyce Liu, Austin Doyle, Neil S Horowitz, Funda Meric-Bernstam, Michael Birrer, Carol Aghajanian, Robert L Coleman, Gordon B Mills, Lewis C Cantley, Ursula A Matulonis, Shannon N Westin (2020). Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. International journal of cancer, 413-422. https://doi.org/10.1002/ijc.32783 PMID: 31714586", "31714586" ], [ "Yan Xing, Nancy U Lin, Matthew A Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco, Dianna Riall, Agda Karina Eterovic, Gerburg M Wulf, Lewis C Cantley, Gordon B Mills, L Austin Doyle, Eric Winer, Gabriel N Hortobagyi, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam (2019). Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast cancer research : BCR, 78. https://doi.org/10.1186/s13058-019-1154-8 PMID: 31277699", "31277699" ], [ "Katy Teo, Laura Gómez-Cuadrado, Milou Tenhagen, Adam Byron, Max Rätze, Miranda van Amersfoort, Jojanneke Renes, Eric Strengman, Amit Mandoli, Abhishek A Singh, Joost H Martens, Hendrik G Stunnenberg, Paul J van Diest, Valerie G Brunton, Patrick W B Derksen (2018). E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. Scientific reports, 15454. https://doi.org/10.1038/s41598-018-33525-5 PMID: 30337563", "30337563" ] ] ], [ [ "PIK3CA", "Cetuximab" ], 4.643587, [ [ "Riham Suleiman, Patrick McGarrah, Binav Baral, Dawn Owen, Jesus Vera Aguilera, Thor R Halfdanarson, Katharine A Price, Harry E Fuentes Bayne (2024). Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancer reports (Hoboken, N.J.), e70023. https://doi.org/10.1002/cnr2.70023 PMID: 39376013", "39376013" ], [ "Simon Haefliger, Katharina Marston, Ilaria Alborelli, Edouard-Jean Stauffer, Mathias Gugger, Philip M Jermann, Sylvia Hoeller, Luigi Tornillo, Luigi M Terracciano, Michel Bihl, Matthias S Matter (2023). Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics. Pathobiology : journal of immunopathology, molecular and cellular biology, 166-175. https://doi.org/10.1159/000526117 PMID: 36202073", "36202073" ], [ "Lu Yang, Arup Bhattacharya, Yun Li, Sandra Sexton, Xiang Ling, Fengzhi Li, Yuesheng Zhang (2022). Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. Journal of experimental & clinical cancer research : CR, 184. https://doi.org/10.1186/s13046-022-02389-z PMID: 35650607", "35650607" ], [ "Axel Wein, Robert Stoehr, Stephan Kersting, Jürgen Siebler, Susanne Merkel, Dagmar Busse, Kerstin Wolff, Nicola Ostermeier, Clemens Neufert, Francesco Vitali, Markus Eckstein, Jan-Peter Roth, Peter Anhut, Waldemar Schreiner, Michael Uder, Arndt Hartmann, Markus F Neurath, Robert Grützmann (2022). A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results. Oncology, 1-11. https://doi.org/10.1159/000519252 PMID: 34670215", "34670215" ], [ "J Sastre, P García-Alfonso, J M Viéitez, M T Cano, F Rivera, J J Reina-Zoilo, A Salud-Salvia, G Quintero, L Robles-Díaz, M J Safont, A La Casta, S Gil, E Polo, E Asensio-Martínez, B García-Paredes, R L López, M Guillot, M Valladares-Ayerbes, E Aranda, E Díaz-Rubio, (2021). Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. ESMO open, 100062. https://doi.org/10.1016/j.esmoop.2021.100062 PMID: 33711671", "33711671" ], [ "Maria Rivera, Iduna Fichtner, Annika Wulf-Goldenberg, Christine Sers, Johannes Merk, Giannino Patone, Keziban M Alp, Tamara Kanashova, Philipp Mertins, Jens Hoffmann, Ulrike Stein, Wolfgang Walther (2021). Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine. Neoplasia (New York, N.Y.), 21-35. https://doi.org/10.1016/j.neo.2020.11.005 PMID: 33212364", "33212364" ], [ "Samuel A Jacobs, James J Lee, Thomas J George, James L Wade, Philip J Stella, Ding Wang, Ashwin R Sama, Fanny Piette, Katherine L Pogue-Geile, Rim S Kim, Patrick G Gavin, Corey Lipchik, Huichen Feng, Ying Wang, Melanie Finnigan, Brian F Kiesel, Jan H Beumer, Norman Wolmark, Peter C Lucas, Carmen J Allegra, Ashok Srinivasan (2021). Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 1612-1622. https://doi.org/10.1158/1078-0432.CCR-20-1831 PMID: 33203645", "33203645" ], [ "Xinhui Fu, Hanjie Lin, Xinjuan Fan, Yaxi Zhu, Chao Wang, Zhiting Chen, Xiaoli Tan, Jinglin Huang, Yacheng Cai, Yan Huang (2021). The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients. Frontiers in oncology, 595675. https://doi.org/10.3389/fonc.2021.595675 PMID: 33842311", "33842311" ], [ "Sanne C F A Huijberts, Mirjam C Boelens, Rene Bernards, Frans L Opdam (2021). Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. British journal of cancer, 176-182. https://doi.org/10.1038/s41416-020-01147-2 PMID: 33204026", "33204026" ], [ "Sun Young Kim, Kwoneel Kim, Su Han Cho, Sung-Min Chun, Eunyoung Tak, Yong Sang Hong, Jeong Eun Kim, Tae Won Kim (2021). Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer. Cancer genetics, 27-36. https://doi.org/10.1016/j.cancergen.2021.06.007 PMID: 34315006", "34315006" ] ] ], [ [ "5XGI Crystal structure of PI3K complex with an inhibitor", "PIK3CA" ], 7.036307399999999 ], [ [ "5DTM Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]", "DOT1L" ], 7.036307399999999 ], [ [ "SOS1", "PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER" ], 2.6114129999999998 ], [ [ "PIK3CA", "Trastuzumab" ], 6.5044113, [ [ "Rong Qin, Xiangyang Wang, Tingting Fan, Ting Wu, Chao Lu, Xun Shao, Liang Yin (2024). Bilateral inflammatory recurrence of HER-2 positive breast cancer: a unique case report and literature review. Frontiers in oncology, 1276637. https://doi.org/10.3389/fonc.2024.1276637 PMID: 38283858", "38283858" ], [ "Asmaa Mohamed Mekhamer, Marwa Hanafi Saied, Dalia Abd Elmoaty Elneily, Tarek Abdel Halim El-Fayoumi, Doaa Ibrahim Hashad (2024). Targeted Sequencing of HER2-Positive Breast Cancer Mutations Revealed a Potential Association between PIK3CA and Trastuzumab Resistance. Asian Pacific journal of cancer prevention : APJCP, 4051-4059. https://doi.org/10.31557/APJCP.2024.25.11.4051 PMID: 39611930", "39611930" ], [ "Diana-Theodora Morgos, Constantin Stefani, Daniela Miricescu, Maria Greabu, Silviu Stanciu, Silvia Nica, Iulia-Ioana Stanescu-Spinu, Daniela Gabriela Balan, Andra-Elena Balcangiu-Stroescu, Elena-Claudia Coculescu, Dragos-Eugen Georgescu, Remus Iulian Nica (2024). Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer. International journal of molecular sciences. https://doi.org/10.3390/ijms25031848 PMID: 38339127", "38339127" ], [ "Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Elena Elez, Javier Rodriguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Makito Koga, Koichiro Inaki, Yusuke Kuwahara, Issey Takehara, Daniel Barrios, Kojiro Kobayashi, Axel Grothey, Takayuki Yoshino (2024). HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nature communications, 10213. https://doi.org/10.1038/s41467-024-53223-3 PMID: 39587050", "39587050" ], [ "Shaimaa Abdel-Ghany, Yasmin Khalid, Soha Mohamed, Gehan Mohamed, Engy Mohdy, Abeer Ezzat, Engy F Madian, Osama A Said, Mohamed A Abdel-Hakeem, Mahmoud Nazih, Ahmed Khoder, Hussein Sabit (2024). Trastuzumab Induces Apoptosis and Cell Cycle Arrest in Triple-Negative Breast Cancer, Suggesting Repurposing Potential. Breast cancer : basic and clinical research, 11782234241285411. https://doi.org/10.1177/11782234241285411 PMID: 39611037", "39611037" ], [ "Qiyun Shi, Juncheng Xuhong, Tao Luo, Jia Ge, Feng Liu, Yang Lan, Qingqiu Chen, Peng Tang, Linjun Fan, Li Chen, Yan Liang, Minghao Wang, Ying Hu, Yi Zhang, Xiuwu Bian, Xiaowei Qi, Jun Jiang (2023). PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. British journal of cancer, 121-129. https://doi.org/10.1038/s41416-022-02021-z PMID: 36323880", "36323880" ], [ "Karine Ronan, Emmet Jordan, Christine Leonard, Ray McDermott (2023). Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data. Irish journal of medical science. https://doi.org/10.1007/s11845-023-03569-2 PMID: 37947995", "37947995" ], [ "Apolonia Novillo, María Gaibar, Alicia Romero-Lorca, Diego Malón, Beatriz Antón, Amalia Moreno, Ana Fernández-Santander (2023). HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment. Cancers. https://doi.org/10.3390/cancers15030763 PMID: 36765720", "36765720" ], [ "Marla Lipsyc-Sharf, Esha Jain, Laura C Collins, Shoshana M Rosenberg, Kathryn J Ruddy, Rulla M Tamimi, Lidia Schapira, Steven E Come, Jeffrey M Peppercorn, Virginia F Borges, Ellen Warner, Craig Snow, Ian E Krop, Dewey Kim, Jakob Weiss, Jorge Gomez Tejeda Zanudo, Ann H Partridge, Nikhil Wagle, Adrienne G Waks (2023). Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. JCO precision oncology, e2300076. https://doi.org/10.1200/PO.23.00076 PMID: 37364233", "37364233" ], [ "Paola Zagami, Aranzazu Fernandez-Martinez, Naim U Rashid, Katherine A Hoadley, Patricia A Spears, Giuseppe Curigliano, Charles M Perou, Lisa A Carey (2023). Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer. JAMA network open, e2348814. https://doi.org/10.1001/jamanetworkopen.2023.48814 PMID: 38117494", "38117494" ] ] ], [ [ "KRAS", "Cetuximab" ], 20.27984, [ [ "John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, Volker Heinemann, Yoshiaki Nakamura, Kanwal Raghav, Salvatore Siena, Josep Tabernero, Eric Van Cutsem, Takayuki Yoshino, Jorge Ramos, Xuesong Guan, Thierry Andre (2024). MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future oncology (London, England), 1-9. https://doi.org/10.1080/14796694.2024.2441101 PMID: 39723627", "39723627" ], [ "John D Mason, Ewan Marks, Shih-Jung Fan, Kristie McCormick, Clive Wilson, Adrian L Harris, Freddie C Hamdy, Chris Cunningham, Deborah C I Goberdhan (2024). Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer. Journal of extracellular vesicles, e12465. https://doi.org/10.1002/jev2.12465 PMID: 38887984", "38887984" ], [ "Saikat Chowdhury, Ria Gupta, Joshua Millstein, Kangyu Lin, Valsala Haridas, Mohammad A Zeineddine, Christine Parseghian, Heinz-Josef Lenz, Scott Kopetz, John Paul Shen (2023). Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer. JCO precision oncology, e2200422. https://doi.org/10.1200/PO.22.00422 PMID: 37487150", "37487150" ], [ "Josep Tabernero, Eric Van Cutsem, Elena Garralda, David Tai, Filippo De Braud, Ravit Geva, Mark T J van Bussel, Katia Fiorella Dotti, Elena Elez, María J de Miguel, Kevin Litwiler, Danielle Murphy, Michelle Edwards, Van Karlyle Morris (2023). A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. The oncologist, 230-238. https://doi.org/10.1093/oncolo/oyad007 PMID: 36811382", "36811382" ], [ "Florinda A Santos, Rui Manuel Reis, Lucas C Barroti, Allan A L Pereira, Marcus M Matsushita, Ana Carolina de Carvalho, José Guilherme Datorre, Gustavo N Berardinelli, Raphael L C Araujo (2023). Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer. Journal of gastrointestinal cancer. https://doi.org/10.1007/s12029-023-00964-x PMID: 37608030", "37608030" ], [ "Pilar García-Alfonso, Astrid Lièvre, Fotios Loupakis, Abir Tadmouri, Sadya Khan, Leticia Barcena, Sebastian Stintzing (2022). Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer. Critical reviews in oncology/hematology, 103646. https://doi.org/10.1016/j.critrevonc.2022.103646 PMID: 35344913", "35344913" ], [ "Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, Ludwig Fischer von Weikersthal, Markus M Lerch, Thomas Decker, Alexander Kiani, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Heinz-Gert Höffkes, Markus Moehler, Alena Britta Gesenhues, Sebastian Theurich, Marlies Michl, Dominik P Modest, Hana Algül, Sebastian Stintzing, Volker Heinemann, Julian W Holch (2022). Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). International journal of cancer, 112-123. https://doi.org/10.1002/ijc.33775 PMID: 34431518", "34431518" ], [ "Wai-Hung Leung, Jing-Wen Shih, Jian-Syun Chen, Ntlotlang Mokgautsi, Po-Li Wei, Yan-Jiun Huang (2022). Preclinical Identification of Sulfasalazine's Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines. https://doi.org/10.3390/biomedicines10020377 PMID: 35203586", "35203586" ], [ "Masaru Matsumura, Kiyoshi Hasegawa, Masaru Oba, Kensei Yamaguchi, Hiroyuki Uetake, Takayuki Yoshino, Satoshi Morita, Keiichi Takahashi, Michiaki Unno, Yasuhiro Shimada, Kei Muro, Nobuhisa Matsuhashi, Masaki Mori, Hideo Baba, Mitsuo Shimada, Yoshihiro Mise, Yoshikuni Kawaguchi, Tatsuo Kagimura, Kiyoshi Ishigure, Akio Saiura, Kenichi Sugihara, Norihiro Kokudo (2022). A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. Langenbeck's archives of surgery, 1345-1356. https://doi.org/10.1007/s00423-022-02434-7 PMID: 35211831", "35211831" ], [ "Glaucia Maria de Mendonça Fernandes, Vilson Serafim Junior, Ana Lívia Silva Galbiatti-Dias, Leticia Antunes Muniz Ferreira, Márcia Maria Urbanin Castanhole-Nunes, Rosa Sayoko Kawasaki-Oyama, José Victor Maniglia, Erika Cristina Pavarino, Eny Maria Goloni-Bertollo (2022). Treatment effects of the EGFR pathway drugs on head and neck cancer stem cells. American journal of cancer research, 4196-4210. PMID: 36225637", "36225637" ] ] ], [ [ "KRAS", "AZD 6244" ], 2.221586, [ [ "Margarita Dionysiou, Stavriani C Makri, Shivani Ahlawat, Melike Guryildirim, Kristin W Barañano, Mari L Groves, Pedram Argani, Christine A Pratilas (2024). Case report: MEK inhibitor as treatment for multi-lineage mosaic KRAS G12D-associated epidermal nevus syndrome in a pediatric patient. Frontiers in neurology, 1466946. https://doi.org/10.3389/fneur.2024.1466946 PMID: 39385823", "39385823" ], [ "Jianan Qiao, Shuhui Liu, Yanfeng Huang, Xiang Zhu, Chenyang Xue, Yan Wang, Hui Xiong, Jing Yao (2024). Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment. Journal of colloid and interface science, 477-490. https://doi.org/10.1016/j.jcis.2024.02.141 PMID: 38429120", "38429120" ], [ "Mark Jackson, Niousha Ahmari, Jianqiang Wu, Tilat A Rizvi, Elizabeth Fugate, Mi-Ok Kim, Eva Dombi, Heribert Arnhof, Guido Boehmelt, Matthias J Düchs, Clive J Long, Udo Maier, Francesca Trapani, Marco H Hofmann, Nancy Ratner (2023). Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. The Journal of pharmacology and experimental therapeutics, 106-116. https://doi.org/10.1124/jpet.122.001431 PMID: 36849412", "36849412" ], [ "Baojun Ren, Yan Geng, Shuxiang Chen, Zhuowei Gao, Kehong Zheng, Yong Yang, Qimei Luo, Jing Feng, Zhentao Luo, Yongle Ju, Zonghai Huang (2023). Alisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines. Experimental and therapeutic medicine, 243. https://doi.org/10.3892/etm.2023.11942 PMID: 37153900", "37153900" ], [ "Wenfang Zheng, Zhiyi Yang, Ping Song, Yingchao Sun, Pan Liu, Lei Yue, Kaiqi Lv, Xinjie Wang, Yuqin Shen, Jianmin Si, Xue Zhang, Yuehai Ke, Hongqiang Cheng, Weiling Hu (2023). SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity. Cancer letters, 216029. https://doi.org/10.1016/j.canlet.2022.216029 PMID: 36493900", "36493900" ], [ "Yahong Liu, Ying Cheng, Gongchao Huang, Xiangying Xia, Xingkai Wang, Hongqi Tian (2023). Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor. Frontiers in pharmacology, 1271268. https://doi.org/10.3389/fphar.2023.1271268 PMID: 37808191", "37808191" ], [ "Wei-Wei Wang, Wei-Qi Wang, Shan-Shan Wang, Lei Pan (2022). The efficacy and safety of selumetinib as secondary therapy for late-stage and metastatic non-small cell lung cancer: results from a systematic review and meta-analysis. Annals of translational medicine, 593. https://doi.org/10.21037/atm-22-1849 PMID: 35722363", "35722363" ], [ "Seyed Pairawan, Argun Akcakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Rizvi, Vijaykumar Holla, Jing Wang, Kurt W Evans, Ming Zhao, Naifa Busaidy, Bingliang Fang, Jack A Roth, Ecaterina Ileana Dumbrava, Funda Meric-Bernstam (2022). Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific reports, 1248. https://doi.org/10.1038/s41598-022-05193-z PMID: 35075200", "35075200" ], [ "Emilie M J van Brummelen, Sanne Huijberts, Carla van Herpen, Ingrid Desar, Frans Opdam, Robin van Geel, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin Huitema, Jos Beijnen, Rene Bernards, Jan Schellens (2021). Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The oncologist, 290-e545. https://doi.org/10.1002/onco.13631 PMID: 33296125", "33296125" ], [ "Francesca Fanini, Erika Bandini, Meropi Plousiou, Silvia Carloni, Petra Wise, Paolo Neviani, Mariam Murtadha, Flavia Foca, Francesco Fabbri, Ivan Vannini, Muller Fabbri (2021). MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer. International journal of molecular sciences. https://doi.org/10.3390/ijms222413357 PMID: 34948154", "34948154" ] ] ], [ [ "DOT1L", "S-Adenosylmethionine" ], 1.3816097, [ [ "Nicole Trainor, Harry J Whitwell, Beatriz Jiménez, Katie Addison, Emily Leonidou, Peter A DiMaggio, Matthew J Fuchter (2024). Tracking DOT1L methyltransferase activity by stable isotope labelling using a selective synthetic co-factor. Communications chemistry, 145. https://doi.org/10.1038/s42004-024-01227-x PMID: 38937590", "38937590" ], [ "Jithesh Kottur, Kris M White, M Luis Rodriguez, Olga Rechkoblit, Richard Quintana-Feliciano, Ahana Nayar, Adolfo García-Sastre, Aneel K Aggarwal (2023). Structures of SARS-CoV-2 N7-methyltransferase with DOT1L and PRMT7 inhibitors provide a platform for new antivirals. PLoS pathogens, e1011546. https://doi.org/10.1371/journal.ppat.1011546 PMID: 37523415", "37523415" ], [ "Pål Ø Falnes, Jędrzej M Małecki, Maria C Herrera, Mads Bengtsen, Erna Davydova (2023). Human seven-β-strand (METTL) methyltransferases - conquering the universe of protein lysine methylation. The Journal of biological chemistry, 104661. https://doi.org/10.1016/j.jbc.2023.104661 PMID: 36997089", "36997089" ], [ "Timothy J Stodola, Young-In Chi, Thiago M De Assuncao, Elise N Leverence, Swarnendu Tripathi, Nikita R Dsouza, Angela J Mathison, Brian F Volkman, Brian C Smith, Gwen Lomberk, Michael T Zimmermann, Raul Urrutia (2022). Computational modeling reveals key molecular properties and dynamic behavior of disruptor of telomeric silencing 1-like (DOT1L) and partnering complexes involved in leukemogenesis. Proteins, 282-298. https://doi.org/10.1002/prot.26219 PMID: 34414607", "34414607" ], [ "Jujun Zhou, John R Horton, Dan Yu, Ren Ren, Robert M Blumenthal, Xing Zhang, Xiaodong Cheng (2022). Repurposing epigenetic inhibitors to target the Clostridioides difficile-specific DNA adenine methyltransferase and sporulation regulator CamA. Epigenetics, 970-981. https://doi.org/10.1080/15592294.2021.1976910 PMID: 34523387", "34523387" ], [ "Federica Sarno, Angela Nebbioso, Lucia Altucci (2020). DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment. Epigenetics, 439-453. https://doi.org/10.1080/15592294.2019.1699991 PMID: 31790636", "31790636" ], [ "Kathy-Ann Secker, Bianca Bloechl, Hildegard Keppeler, Silke Duerr-Stoerzer, Hannes Schmid, Dominik Schneidawind, Johan Jeong, Thomas Hentrich, Julia M Schulze-Hentrich, Corina Schneidawind (2020). MAT2A as Key Regulator and Therapeutic Target in MLLr Leukemogenesis. Cancers. https://doi.org/10.3390/cancers12051342 PMID: 32456310", "32456310" ], [ "Julia Gobl, Deepak Kumar Sinha, Radek Sima, Jan Perner, Petr Kopáček, James J Valdés, Ryan O M Rego, Alejandro Cabezas-Cruz (2020). Histone Methyltransferase DOT1L is Involved in Larval Molting and Second Stage Nymphal Feeding in Ornithodoros Moubata. Vaccines. https://doi.org/10.3390/vaccines8020157 PMID: 32244625", "32244625" ], [ "Aditya Barve, Alexis Vega, Parag P Shah, Smita Ghare, Lavona Casson, Mark Wunderlich, Leah J Siskind, Levi J Beverly (2019). Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia. Cells. https://doi.org/10.3390/cells8111322 PMID: 31717699", "31717699" ], [ "Jie Chen, Hyun-Ju Park (2019). Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor. ACS chemical biology, 873-881. https://doi.org/10.1021/acschembio.8b00933 PMID: 30951287", "30951287" ] ] ], [ [ "SOS1", "trametinib" ], 11.789075, [ [ "Benjamin Schulz, Emily Leitner, Tim Schreiber, Tobias Lindner, Rico Schwarz, Nadine Aboutara, Yixuan Ma, Hugo Murua Escobar, Rupert Palme, Burkhard Hinz, Brigitte Vollmar, Dietmar Zechner (2024). Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. Cancers. https://doi.org/10.3390/cancers16101901 PMID: 38791980", "38791980" ], [ "Elisabetta Puliga, Chiara De Bellis, Sandra Vietti Michelina, Tania Capeloa, Cristina Migliore, Claudia Orrù, Gian Luca Baiocchi, Giovanni De Manzoni, Filippo Pietrantonio, Rossella Reddavid, Uberto Fumagalli Romario, Chiara Ambrogio, Simona Corso, Silvia Giordano (2024). Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 473-483. https://doi.org/10.1007/s10120-024-01468-8 PMID: 38261067", "38261067" ], [ "Brianna R Daley, Heidi M Vieira, Chaitra Rao, Jacob M Hughes, Zaria M Beckley, Dianna H Huisman, Deepan Chatterjee, Nancy E Sealover, Katherine Cox, James W Askew, Robert A Svoboda, Kurt W Fisher, Robert E Lewis, Robert L Kortum (2023). SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status. Proceedings of the National Academy of Sciences of the United States of America, e2313137120. https://doi.org/10.1073/pnas.2313137120 PMID: 37972068", "37972068" ], [ "Guy Chowers, Gadi Abebe-Campino, Hana Golan, Asaf Vivante, Shoshana Greenberger, Michalle Soudack, Galia Barkai, Ilana Fox-Fisher, Dong Li, Michael March, Mark R Battig, Hakon Hakonarson, Denise Adams, Yoav Dori, Adi Dagan (2023). Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition. Pediatric research, 1911-1915. https://doi.org/10.1038/s41390-022-01986-0 PMID: 35246606", "35246606" ], [ "Michele Lioncino, Adelaide Fusco, Emanuele Monda, Diego Colonna, Michelina Sibilio, Martina Caiazza, Daniela Magri, Angela Carla Borrelli, Barbara D'Onofrio, Maria Luisa Mazzella, Rossella Colantuono, Maria Rosaria Arienzo, Berardo Sarubbi, Maria Giovanna Russo, Giovanni Chello, Giuseppe Limongelli (2022). Severe Lymphatic Disorder and Multifocal Atrial Tachycardia Treated with Trametinib in a Patient with Noonan Syndrome and SOS1 Mutation. Genes. https://doi.org/10.3390/genes13091503 PMID: 36140671", "36140671" ], [ "Yixuan Ma, Benjamin Schulz, Nares Trakooljul, Moosheer Al Ammar, Anett Sekora, Sina Sender, Frieder Hadlich, Dietmar Zechner, Frank Ulrich Weiss, Markus M Lerch, Robert Jaster, Christian Junghanss, Hugo Murua Escobar (2022). Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers. https://doi.org/10.3390/cancers14184467 PMID: 36139627", "36139627" ], [ "Adelina Plangger, Barbara Rath, Sandra Stickler, Maximilian Hochmair, Clemens Lang, Lukas Weigl, Martin Funovics, Gerhard Hamilton (2022). Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines. Discover. Oncology, 84. https://doi.org/10.1007/s12672-022-00550-w PMID: 36048281", "36048281" ], [ "Takamasa Koga, Kenichi Suda, Toshio Fujino, Shuta Ohara, Akira Hamada, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Takeo Arita, Michael Gmachl, Marco H Hofmann, Junichi Soh, Tetsuya Mitsudomi (2021). KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 1321-1332. https://doi.org/10.1016/j.jtho.2021.04.015 PMID: 33971321", "33971321" ], [ "Yoav Dori, Chris Smith, Erin Pinto, Kristen Snyder, Michael E March, Hakon Hakonarson, Jean Belasco (2020). Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation. Pediatrics. https://doi.org/10.1542/peds.2020-0167 PMID: 33219052", "33219052" ], [ "Gabrielle S Wong, Jin Zhou, Jie Bin Liu, Zhong Wu, Xinsen Xu, Tianxia Li, David Xu, Steven E Schumacher, Jens Puschhof, James McFarland, Charles Zou, Austin Dulak, Les Henderson, Peng Xu, Emily O'Day, Rachel Rendak, Wei-Li Liao, Fabiola Cecchi, Todd Hembrough, Sarit Schwartz, Christopher Szeto, Anil K Rustgi, Kwok-Kin Wong, J Alan Diehl, Karin Jensen, Francesco Graziano, Annamaria Ruzzo, Shaunt Fereshetian, Philipp Mertins, Steven A Carr, Rameen Beroukhim, Kenichi Nakamura, Eiji Oki, Masayuki Watanabe, Hideo Baba, Yu Imamura, Daniel Catenacci, Adam J Bass (2018). Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature medicine, 968-977. https://doi.org/10.1038/s41591-018-0022-x PMID: 29808010", "29808010" ] ] ], [ [ "KRAS", "Fluorouracil" ], 9.655294, [ [ "Tasvi Daya, Andrea Breytenbach, Liang Gu, Mandeep Kaur (2024). Cholesterol metabolism in pancreatic cancer and associated therapeutic strategies. Biochimica et biophysica acta. Molecular and cell biology of lipids, 159578. https://doi.org/10.1016/j.bbalip.2024.159578 PMID: 39542394", "39542394" ], [ "Victoria Chung, Jonathan D Mizrahi, Shubham Pant (2024). Novel Therapies for Pancreatic Cancer. JCO oncology practice, OP2400279. https://doi.org/10.1200/OP.24.00279 PMID: 39591547", "39591547" ], [ "Juhi Mody, Mandana Kamgar (2024). Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review. Case reports in oncology, 399-406. https://doi.org/10.1159/000536552 PMID: 38435447", "38435447" ], [ "Keun-Wook Lee, Sae-Won Han, Tae Won Kim, Joong Bae Ahn, Ji Yeon Baek, Sang Hee Cho, Howard Lee, Jin Won Kim, Ji-Won Kim, Tae-You Kim, Yong Sang Hong, Seung-Hoon Beom, Yongjun Cha, Yoonjung Choi, Seonhui Kim, Yung-Jue Bang (2023). A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer. Cancer research and treatment. https://doi.org/10.4143/crt.2023.1117 PMID: 38062706", "38062706" ], [ "Sora Kang, Myung-Won Lee, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Deog-Yeon Jo, Jung Sun Kim, Jung Hye Kwon, Ji-Yeon Kim, Kyung-Ha Lee, Hyewon Ryu (2023). Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAFV600E mutation status. Journal of cancer research and clinical oncology, 7819-7829. https://doi.org/10.1007/s00432-023-04720-3 PMID: 37031435", "37031435" ], [ "Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, Ludwig Fischer von Weikersthal, Markus M Lerch, Thomas Decker, Alexander Kiani, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Heinz-Gert Höffkes, Markus Moehler, Alena Britta Gesenhues, Sebastian Theurich, Marlies Michl, Dominik P Modest, Hana Algül, Sebastian Stintzing, Volker Heinemann, Julian W Holch (2022). Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). International journal of cancer, 112-123. https://doi.org/10.1002/ijc.33775 PMID: 34431518", "34431518" ], [ "Masaru Matsumura, Kiyoshi Hasegawa, Masaru Oba, Kensei Yamaguchi, Hiroyuki Uetake, Takayuki Yoshino, Satoshi Morita, Keiichi Takahashi, Michiaki Unno, Yasuhiro Shimada, Kei Muro, Nobuhisa Matsuhashi, Masaki Mori, Hideo Baba, Mitsuo Shimada, Yoshihiro Mise, Yoshikuni Kawaguchi, Tatsuo Kagimura, Kiyoshi Ishigure, Akio Saiura, Kenichi Sugihara, Norihiro Kokudo (2022). A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. Langenbeck's archives of surgery, 1345-1356. https://doi.org/10.1007/s00423-022-02434-7 PMID: 35211831", "35211831" ], [ "Arata Nishimoto (2022). Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World journal of gastroenterology, 3637-3643. https://doi.org/10.3748/wjg.v28.i28.3637 PMID: 36161054", "36161054" ], [ "Min Shi, Hong Yuan, Jun Ji, Shouwei Zhang, Qingyuan Li, Yawei Chen, Xiaoli Gong, Zhenggang Zhu, Jun Zhang (2022). Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer. Therapeutic advances in medical oncology, 17588359211070643. https://doi.org/10.1177/17588359211070643 PMID: 35096147", "35096147" ], [ "Y Sunakawa, H Satake, J Usher, Y Jaimes, Y Miyamoto, M Nakamura, M Kataoka, M Shiozawa, A Takagane, T Terazawa, T Watanabe, K Ishiguro, C Tanaka, M Takeuchi, M Fujii, K Danenberg, P V Danenberg, H-J Lenz, T Sekikawa, W Ichikawa (2022). Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). ESMO open, 100512. https://doi.org/10.1016/j.esmoop.2022.100512 PMID: 35688061", "35688061" ] ] ], [ [ "5DTM Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]", "4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide" ], 7.036307399999999 ], [ [ "DOT1L", "Etoposide" ], 0.73656195, [ [ "Yu Mao, Yu Sun, Zhixuan Wu, Jingzhi Zheng, Jianing Zhang, Jiaqi Zeng, Chunsik Lee, Jong Kyong Kim (2021). Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy. Cell death & disease, 1141. https://doi.org/10.1038/s41419-021-04431-y PMID: 34887387", "34887387" ], [ "Li-Hong Li, Jing Wang, Xiao-Yan Ke (2017). [Effects of DOT1L Inhibitor EPZ-5676 Combined with Chemotherapeutic Drugs on Prolifiration and Apoptosis of RS 4;11 Cells]. Zhongguo shi yan xue ye xue za zhi, 1334-1341. https://doi.org/10.7534/j.issn.1009-2137.2017.05.010 PMID: 29070104", "29070104" ], [ "Wei Liu, Lisheng Deng, Yongcheng Song, Michele Redell (2014). DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PloS one, e98270. https://doi.org/10.1371/journal.pone.0098270 PMID: 24858818", "24858818" ] ] ] ] }